Q2 2026 13F · SEC CIK 1569241
Newtyn Management, LLC
Hedge fundFiled 2026-08-14 for Q2 2026. Open the filing ↗ · All SEC filings ↗
- Reported 13F value
- $800.9M
- Reported positions
- 34
- Top holdings a year, 3 yrs
- -3.8%
- Assets under management
- $2.1B
Newtyn Management, LLC is a hedge fund that reported 34 positions worth $800.9M in its Q2 2026 13F, filed 2026-08-14. Its largest holdings were Quidelortho Corp (QDEL, 14.5%), Theravance Biopharma Inc (TBPH, 7.3%), Indivior Pharmaceuticals Inc (INDV, 6.7%). A portfolio copying its top holdings returned -3.8% a year over the last 3 years, against 20.4% for the S&P 500.
Newtyn Management, LLC holdings all 34 positions.
Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.
What Newtyn Management, LLC bought and sold in Q2 2026, against Q1 2026.
New positions
- OCTVV Octave Intelligence PLC3.9% of 13F
- XOMA Xoma Royalty Corporation3.8% of 13F
- PSIX Power Solutions Intl Inc2.9% of 13F
- XRN Chiron Real Estate Inc1.9% of 13F
- NVRI Enviri Corp1.0% of 13F
- VCX Fundrise Innovation Fd LLC0.4% of 13F
- ZOOZ Zooz Strategy Ltd0.4% of 13F
- ENHA Enhanced Group Inc0.0% of 13F
Added to
- SRG Seritage Growth Properties+5411.3% shares
- GDOT Green Dot Corp+743.7% shares
- WRE Elme Communities+705.8% shares
- QDEL Quidelortho Corp+45.3% shares
- RCKT Rocket Pharmaceuticals Inc+26.3% shares
Reduced
- AD Array Digital Infrastructure-63.1% shares
- MREO Mereo Biopharma Group PLC-57.6% shares
- INDV Indivior Pharmaceuticals Inc-34.7% shares
- ATAI Ataibeckley Inc-33.3% shares
- TBPH Theravance Biopharma Inc-29.1% shares
- WVE Wave Life Sciences Ltd-28.3% shares
- TFX Teleflex Incorporated-23.8% shares
- CMP Compass Minerals International, Inc.-17.9% shares
Sold out
- HSC Enviri Corpwas 11.5%
- VISN Vistance Networks Incwas 7.3%
- USAR USA Rare Earth Incwas 3.8%
- DXYZ Destiny Tech100 Incwas 1.0%
- RARE Ultragenyx Pharmaceutical inwas 0.9%
- Zooz Strategy Ltdwas 0.4%
- QURE Uniqure NVwas 0.2%
Share counts compared with the Q1 2026 13F; a split also changes share counts.
How the holdings did against the S&P 500.
- 1 year
- -15.0% /yr
- S&P 500 +20.1%
- 3 years
- -3.8% /yr
- S&P 500 +20.4%
- 5 years
- -5.3% /yr
- S&P 500 +11.6%
A portfolio of the filer's 20 largest 13F positions, weighted by value, bought the trading day after each 13F was filed and held until the next one was: what copying this filer could have earned. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.
Reported 13F value by quarter.
| Quarter | 13F value | Positions |
|---|---|---|
| Q2 2026 | $800.9M | 34 |
| Q1 2026 | $935.8M | 33 |
| Q4 2025 | $945.3M | 31 |
| Q3 2025 | $816.9M | 33 |
| Q2 2025 | $660.0M | 34 |
| Q1 2025 | $632.1M | 31 |
| Q4 2024 | $574.3M | 33 |
| Q3 2024 | $648.7M | 39 |
| Q2 2024 | $527.2M | 39 |
| Q1 2024 | $496.5M | 39 |
| Q4 2023 | $504.0M | 47 |
| Q3 2023 | $399.8M | 45 |
Questions about Newtyn Management, LLC's portfolio
What stocks does Newtyn Management, LLC own?
Newtyn Management, LLC's latest 13F, for Q2 2026 and filed Aug 14, 2026, lists 34 positions worth $800.9M. The largest are Quidelortho Corp (QDEL) at 14.5%, Theravance Biopharma Inc (TBPH) at 7.3%, Indivior Pharmaceuticals Inc (INDV) at 6.7%, Cannae Hldgs Inc (CNNE) at 5.7% and Par Technology Corp (PAR) at 5.3%.
What did Newtyn Management, LLC buy last quarter?
In Q2 2026, Newtyn Management, LLC added a new position in Octave Intelligence PLC (OCTVV), a new position in Xoma Royalty Corporation (XOMA), a new position in Power Solutions Intl Inc (PSIX), a new position in Chiron Real Estate Inc (XRN), a new position in Enviri Corp (NVRI), Seritage Growth Properties (SRG) (+5411.3% shares), Green Dot Corp (GDOT) (+743.7% shares) and Elme Communities (WRE) (+705.8% shares), compared with its Q1 2026 filing.
What did Newtyn Management, LLC sell last quarter?
In Q2 2026, Newtyn Management, LLC sold all of Enviri Corp (HSC), sold all of Vistance Networks Inc (VISN), sold all of USA Rare Earth Inc (USAR), sold all of Destiny Tech100 Inc (DXYZ), sold all of Ultragenyx Pharmaceutical in (RARE), Array Digital Infrastructure (AD) (-63.1% shares), Mereo Biopharma Group PLC (MREO) (-57.6% shares) and Indivior Pharmaceuticals Inc (INDV) (-34.7% shares), compared with its Q1 2026 filing.
How has Newtyn Management, LLC's portfolio performed?
A portfolio copying Newtyn Management, LLC's 20 largest 13F holdings each quarter, from the day each filing was public, returned -3.8% a year over the last 3 years, against +20.4% for the S&P 500. Over 1 year: -15.0% against +20.1%. Over 5 years: -5.3% a year against +11.6%.
When is Newtyn Management, LLC's next 13F filing due?
13F filings are due 45 days after each quarter ends. Newtyn Management, LLC's filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.
How much money does Newtyn Management, LLC manage?
Newtyn Management, LLC reported $2.1B of regulatory assets under management on its latest SEC Form ADV. Its 13F, which covers only US-listed stocks and options, totals $800.9M.